Avedro said today that it won a date with the FDA next week for its corneal cross-linking technology for treating a pair of eye conditions.
A joint meeting of the watchdog agency’s Dermatologic & Ophthalmic Drugs Advisory Committee and its Ophthalmic Devices Panel is slated for Feb. 24, Boston-based Avedro said.